Psyence Biomedical Ltd. (PBMWW) cash flow statement

PBMWWNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBM

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 22, 2026Score 0/30

$0.01+0.00 (0.00%)

Close on Nov 2, 2026Market cap –P/E –Yield –

Psyence Biomedical Ltd. cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31
Stock-Based Compensation	0.16	–	0.32	0.22
Operating Cash Flow	-8.14	-3.73	-2.95	-1.59
Capital Expenditures	0.00	-0.01	-0.01	–
Investing Cash Flow	-4.51	-0.02	-0.01	–
Stock Issued	–	1.74	–	–
Debt Issued	–	1.00	2.50	–
Debt Repaid	–	–	-0.15	–
Financing Cash Flow	14	9.15	2.35	1.17
Net Change in Cash	1.31	5.40	-0.60	-0.42
Free Cash Flow	-8.14	-3.74	-2.95	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –